• 1. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Recent Advances in the Study of 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid (CAS: 887408-90-4)

The compound 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid (CAS: 887408-90-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This pyrazole derivative has been the subject of numerous studies aimed at elucidating its pharmacological properties, synthetic pathways, and biological activities. This research brief provides an overview of the latest findings related to this compound, highlighting its significance in drug discovery and development.

Recent studies have focused on the synthesis and optimization of 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid, with particular emphasis on improving its yield and purity. Advanced synthetic techniques, such as microwave-assisted synthesis and catalytic methods, have been employed to achieve higher efficiency and reduced reaction times. These advancements are critical for scaling up production and ensuring the compound's availability for further preclinical and clinical studies.

In terms of biological activity, 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid has demonstrated promising anti-inflammatory and analgesic properties in vitro and in vivo models. Mechanistic studies suggest that the compound exerts its effects through the modulation of key inflammatory pathways, including the inhibition of cyclooxygenase (COX) enzymes and the suppression of pro-inflammatory cytokine production. These findings position the compound as a potential candidate for the development of novel anti-inflammatory drugs.

Furthermore, recent research has explored the compound's potential applications in oncology. Preliminary data indicate that 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid may exhibit antiproliferative effects against certain cancer cell lines, particularly those associated with solid tumors. The compound's ability to induce apoptosis and inhibit angiogenesis has been a focal point of these investigations, although further studies are needed to fully understand its mechanisms of action and therapeutic potential.

Pharmacokinetic and toxicological studies of 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid have also been conducted to assess its safety profile. Results from these studies indicate that the compound exhibits favorable bioavailability and a relatively low toxicity profile, making it a viable candidate for further development. However, additional preclinical studies are required to evaluate its long-term effects and potential drug-drug interactions.

In conclusion, 3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)propanoic acid (CAS: 887408-90-4) represents a promising compound with diverse therapeutic applications. Its anti-inflammatory, analgesic, and potential anticancer properties, coupled with its favorable pharmacokinetic profile, underscore its potential as a lead compound in drug discovery. Continued research efforts are essential to fully elucidate its mechanisms of action and to advance its development into clinically viable therapeutics.

• 381679-93-2(3-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-yl)-propionic Acid)
• 1006446-72-5(3-(1-ethyl-5-methyl-1H-pyrazol-4-yl)propanoic acid)
• 1019071-94-3(3-4-(2-Carboxyethyl)-3,5-dimethyl-1H-pyrazol-1-ylpropanoic Acid)
• 1019074-26-0(3-1-(2-Cyanoethyl)-3,5-dimethyl-1H-pyrazol-4-ylpropanoic Acid)
• 1154582-83-8(3-{3,5-Dimethyl-1-(4-methylphenyl)methyl-1H-pyrazol-4-yl}propanoic Acid)
• 2228333-04-6(2-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)butanoic acid)
• 2227847-13-2((3S)-3-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)-3-hydroxypropanoic acid)
• 956371-97-4(3-(1-ethyl-3-methyl-1H-pyrazol-4-yl)propanoic acid)
• 956935-28-7(2-(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)acetic acid)
• 956438-19-0(3-3,5-dimethyl-1-(2-methylpropyl)-1H-pyrazol-4-ylpropanoic Acid)